Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
BackgroundDuring the current pandemic, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralization capacity of the immunoglobulin (IG) supply has changed from undetectable for lots manufactured from plasma collected before the pandemic, to now highly potent.ObjectiveAs antibodies...
Main Authors: | Maria R. Farcet, Julia Schwaiger, Michael Karbiener, Thomas R. Kreil |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.924426/full |
Similar Items
-
Immunoglobulin: production, mechanisms of action and formulations
by: Marcia Cristina Zago Novaretti, et al.
Published: (2011-10-01) -
Plasma therapy: a passive resistance against the deadliest
by: Anita Hansda, et al.
Published: (2022-04-01) -
Successful Desensitization in a Patient with Donor-Specific Antibodies Persisting after Pretransplant Immunosuppression Using Intravenous Immunoglobulin and Plasma Exchange
by: Rohit Kapoor, et al.
Published: (2024-06-01) -
West Nile Virus Infection in Plasma of Blood and Plasma Donors, United States
by: Christina B. Planitzer, et al.
Published: (2009-10-01) -
Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01)